Hematologic Malignancies Detection Market Report 2026

The hematologic malignancies detection market size has grown rapidly in recent years. It will grow from $3.1 billion in 2025 to $3.57 billion in 2026 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to increasing prevalence of blood cancers, adoption of pcr and immunochemistry techniques, expansion of clinical laboratory infrastructure, growing awareness of early cancer detection, availability of advanced diagnostic kits.

The hematologic malignancies detection market size is expected to see rapid growth in the next few years. It will grow to $6.28 billion in 2030 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to increasing adoption of liquid biopsy diagnostics, rising investments in precision oncology, expansion of genomic testing programs, growing use of ai-based diagnostic platforms, increasing focus on early and accurate cancer detection. Major trends in the forecast period include increasing adoption of molecular diagnostic techniques, rising use of next generation sequencing in oncology, growing integration of ai in diagnostic interpretation, expansion of early cancer screening programs, enhanced focus on personalized oncology diagnostics.

The rising prevalence of blood cancer is expected to drive growth in the hematologic malignancy detection market in the coming years. Blood cancer comprises a group of cancers affecting the blood, bone marrow, or lymphatic system, disrupting normal blood cell production and function. Its increasing prevalence is influenced by aging populations and advances in diagnostic technologies that enable earlier and more accurate detection. Hematologic malignancy detection is critical for effective treatment, as it allows for timely and precise diagnosis, supporting personalized treatment strategies. For example, in March 2024, the Leukemia & Lymphoma Society, a US-based professional organization, reported in its Cancer Facts & Figures 2023 report that approximately 437,337 people in the US were living with or in remission from leukemia, with around 59,610 new cases expected to be diagnosed in 2024. Therefore, the growing prevalence of blood cancer is driving the hematologic malignancy detection market.

Leading companies in the hematologic malignancy detection market are focusing on technological advancements and innovative solutions, such as blood cancer diagnostic tests, to improve diagnostic accuracy and patient outcomes. These tests are essential for detecting and confirming hematologic malignancies, including leukemia, lymphoma, and multiple myeloma. For instance, in November 2023, Roswell Park Comprehensive Cancer Center, a US-based research and treatment institution, launched PanHeme, an advanced blood cancer diagnostic test utilizing next-generation gene sequencing technology. PanHeme identifies genetic mutations in blood cancers within 72 hours, significantly faster than traditional methods, enabling healthcare providers to develop personalized treatment plans using targeted FDA-approved therapies based on specific mutations.

In April 2025, NeoGenomics Inc., a US-based cancer diagnostics company, acquired Pathline LLC for an undisclosed sum. The acquisition aims to strengthen NeoGenomics’ commercial presence in the Northeast U.S., expand access to its comprehensive oncology testing menu, and broaden its molecular and hematology-oncology testing services. Pathline LLC is a US-based laboratory providing certified diagnostic testing to support oncologists, hospitals, and healthcare providers with accurate and high-quality laboratory analyses.

Major companies operating in the hematologic malignancies detection market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Roche Diagnostics International Ltd., Illumina Inc., Agilent Technologies Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Becton Dickinson and Company, Beckman Coulter Inc., Sysmex Corporation, Adaptive Biotechnologies Corporation, NeoGenomics Laboratories Inc., Invivoscribe Technologies Inc., ArcherDx Inc., Invitae Corporation, Natera Inc., Genetron Health, SOPHiA GENETICS, Guardant Health Inc., Genetica Diagnostics.

North America was the largest region in the hematologic malignancies’ detection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematologic malignancies detection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hematologic malignancies detection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the hematologic malignancies detection market by increasing costs of imported reagents, sequencing platforms, diagnostic instruments, probes, and analytical software. Diagnostic laboratories and hospitals in North America and Europe are most affected due to dependence on imported advanced testing technologies, while Asia-Pacific faces higher costs for specialized detection kits. These tariffs are increasing test prices and slowing technology upgrades. However, they are also encouraging domestic reagent manufacturing, regional kit production, and local innovation in cost-effective hematologic cancer diagnostics.

The hematologic malignancies detection market research report is one of a series of new reports that provides hematologic malignancies detection market statistics, including hematologic malignancies detection industry global market size, regional shares, competitors with a hematologic malignancies detection market share, detailed hematologic malignancies detection market segments, market trends and opportunities, and any further data you may need to thrive in the hematologic malignancies detection industry. This hematologic malignancies detection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hematologic malignancy detection involves identifying cancers that affect the blood, bone marrow, and lymphatic system. These malignancies include various types of cancers, such as leukemia, lymphoma, and multiple myeloma, which disrupt normal blood cell production and function.

The primary methods of hematologic malignancy detection include polymerase chain reaction (PCR), immunochemistry, next-generation sequencing, fluorescence in situ hybridization (FISH), and others. PCR is a technique used to amplify small amounts of DNA, facilitating the analysis and detection of genetic mutations or abnormalities associated with hematologic malignancies. This method is applied to conditions such as multiple myeloma, myelodysplastic syndromes, leukemia, myeloproliferative neoplasms, lymphoma, and more. These detection techniques are utilized by a range of end users, including hospitals, specialty clinics, homecare providers, and other healthcare facilities.

The hematologic malignancy detection market consists of revenues earned by entities by providing services such as diagnostic testing, imaging studies, clinical evaluation, genetic counseling, and monitoring and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The hematologic malignancy detection market also includes sales of products including bone marrow aspiration and biopsy kits, flow cytometers, fluorescence in situ hybridization (FISH), and IHC staining kits. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.